Oncocyte Corporation Q3 2024 Shareholder Letter

Oncocyte Corporation (NASDAQ: OCX), a diagnostics technology company, has released its third-quarter earnings report and accompanying letter to shareholders, highlighting its progress in commercializing its transplant rejection testing technology, GraftAssure. The report details the signing of new research customers and the progress of their FDA pre-submission process to approve a clinical kitted test. Oncocyte also emphasizes its commitment to building a customer base for future revenue growth and provides updates on its financial performance and scientific advancements.